Well done on purchasing SIP and hanging on , similar to myself....

Well done on purchasing SIP and hanging on , similar to myself. Just one correction in your post is that MYX is not a wholesaler and not in competition with SIP and API. MYX is a generic drug company only. The other player in Australian Pharmacy wholesale is Symbion , which is owned by Ebos ( code EBO ) which has dual listing in Aust and NZ. SIP has had it's problems , with the massive goodwill write down in its generics business , criminal charges and class action. The sale of it's generic business to Sth African company Aspen which enable SIP to become debt free was a turning point. The problem moving forward , as you rightly pointed out , is to increase nett profit. For this to happen SIP has to look outside the wholesale distribution area , which is too regulated by government , and find new areas . One area I think is of vital importance in hospital supply . Mark Hooper has indicated that is an area that interests them. SIP was always under priced against API , but the question was was API overvalued or SIP undervalued, it seems to be the latter.